A study on 462 anemic patients with end stage renal failure on chronic hemodialysis demonstrated the therapeutic equivalence in maintaining the Hb concentration of epoetin zeta and epoetin alfa administered subcutaneously [11]. The gene discussed is GSTM1; the disease is stage 5 chronic kidney disease.